Research and Development Agreements (Tables) |
12 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Dec. 31, 2022 | ||||||||||||||||||||||||||||||||||||||||||||||
| Research And Development [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||
| Schedule of Research and Development Revenues Disaggregated by Location |
Research and Development revenue is attributable to regions based on the location of our collaboration partner's parent company headquarters. Research and Development revenues disaggregated by location were as follows (in thousands):
|
|||||||||||||||||||||||||||||||||||||||||||||
| Schedule of Research and Development Revenue from Related Party Relates to Revenue from Research and Development Agreements |
Research and development revenue from a previously related party was with Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited (“Takeda”) and were as follows (in thousands):
|
|||||||||||||||||||||||||||||||||||||||||||||
| X | ||||||||||
- Definition Schedule of revenue from related party relates to research and development. No definition available.
|
| X | ||||||||||
- Definition Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- References No definition available.
|